Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5249012 | 0.83 | SMN1; SMN2 (0.57) | MAPTHSD17B10SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL34672 | 0.82 | ALDH1A1 (0.66) | MAPTHSD17B10SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5561006 | 0.82 | SMN1; SMN2 (0.56) | MAPTHSD17B10SMN1; SMN2ALDH1A1LMNA | |
| Lithium Ion SCHEMBL22638688 | 0.80 | CA1 (0.61) | MAPTHSD17B10SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11595449 | 0.80 | MEN1 (0.45) | MAPTHSD17B10SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4639473 | 0.80 | CA2 (0.59) | MAPTHSD17B10SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6855109 | 0.80 | SMN1; SMN2 (0.54) | MAPTHSD17B10SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2492611 | 0.79 | HTT (0.61) | MAPTHSD17B10SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2005622 | 0.78 | MEN1 (0.63) | MAPTHSD17B10SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6406510 | 0.78 | MAPT (0.50) | MAPTHSD17B10SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254083-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4337206-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | Libra Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2022240992-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| CN-109153642-B | Indole and azaindole halogenated allylamine derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2022-05-17 | — | — | CN | disclosed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10717734-B2 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | PHARMAXIS LTD. (AU) | 2020-07-21 | — | — | US | disclosed |
| US-20190119269-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2019-04-25 | — | — | US | disclosed |
| EP-3414226-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | Pharmaxis Ltd. (AU) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017136871-A9 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2018-02-15 | — | — | WO | disclosed |
| WO-2017136871-A9 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2018-02-15 | — | — | WO | disclosed |
| WO-2017136871-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017136871-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2017-08-17 | — | — | WO | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1748980-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005115977-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254083-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | TRPM2, TRPM7, TRPM8 | MAPT 1870/4885HSD17B10 3856/4885SMN1; SMN2 2052/4885 |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | MAPT 4734/4885HSD17B10 1741/4885SMN1; SMN2 4282/4885 |
| US-10717734-B2 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | IDO1, IDO2, INMT | MAPT 3527/4885HSD17B10 808/4885SMN1; SMN2 4655/4885 |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | MAPT 2307/4885HSD17B10 3354/4885SMN1; SMN2 1003/4885 |
| US-20190119269-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | MAPT 3527/4885HSD17B10 808/4885SMN1; SMN2 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.